The effect of transmitted HIV-1 drug resistance on pre-therapy viral load.

HIV-1 treatment as prevention: the good, the bad, and the challenges. Curr Opin HIV AIDS (2011) 3.39

Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa. J Infect Dis (2013) 1.77

Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol (2012) 1.36

Assessing predicted HIV-1 replicative capacity in a clinical setting. PLoS Pathog (2011) 1.06

HIV controllers: a multifactorial phenotype of spontaneous viral suppression. Clin Immunol (2011) 1.02

A strong case for viral genetic factors in HIV virulence. Viruses (2011) 1.01

Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load. PLoS One (2011) 0.99

Innate and Adaptive Immunity in Long-Term Non-Progression in HIV Disease. Front Immunol (2013) 0.91

Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population. PLoS One (2011) 0.89

Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City. J Acquir Immune Defic Syndr (2012) 0.89

Viral factors in non-progression. Front Immunol (2013) 0.82

The natural history of HIV infection. Curr Opin HIV AIDS (2013) 0.78

Characteristics of plasmacytoid dendritic cell and CD4+ T cell in HIV elite controllers. Clin Dev Immunol (2012) 0.77

Transmitted HIV drug resistance in treatment-naive Romanian patients. J Med Virol (2013) 0.77

Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93

Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One (2009) 8.37

Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet (2008) 7.70

The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet (2014) 6.69

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20

Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care (2008) 4.10

Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet (2012) 3.94

HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS (2007) 3.94

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry (2002) 3.89

Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (2011) 3.72

British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67

Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med (2008) 3.66

2011 update of the drug resistance mutations in HIV-1. Top Antivir Med (2011) 3.66

Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59

Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med (2013) 3.58

Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med (2009) 3.52

Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS (2010) 3.47

Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis (2009) 3.37

Full-genome deep sequencing and phylogenetic analysis of novel human betacoronavirus. Emerg Infect Dis (2013) 3.35

Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS (2013) 3.30

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis (2010) 3.30

Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17

Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis (2008) 3.15

Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA (2011) 3.08

Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med (2006) 3.06

Genetic analysis reveals the complex structure of HIV-1 transmission within defined risk groups. Proc Natl Acad Sci U S A (2005) 3.04

Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog (2009) 2.92

Update of the Drug Resistance Mutations in HIV-1. Top HIV Med (2008) 2.91

Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med (2010) 2.91

Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology (2010) 2.90

Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med (2007) 2.79

Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis (2005) 2.73

Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials (2012) 2.71

Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil (2010) 2.70

The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. J Infect (2013) 2.66

The gibberellin pathway mediates KNOTTED1-type homeobox function in plants with different body plans. Curr Biol (2002) 2.61

Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis (2013) 2.60

KNOX action in Arabidopsis is mediated by coordinate regulation of cytokinin and gibberellin activities. Curr Biol (2005) 2.54

Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS (2005) 2.51

Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ (2005) 2.51

Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS (2007) 2.47

Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS (2005) 2.45

Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. AIDS (2011) 2.44

HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapy. AIDS (2004) 2.35

Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines. Clin Infect Dis (2011) 2.30

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med (2012) 2.24

Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc Natl Acad Sci U S A (2009) 2.21

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.). HIV Med (2014) 2.18

Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14

Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution. J Infect Dis (2011) 2.13

Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. AIDS (2013) 2.11

Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom. PLoS Pathog (2009) 2.10

HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06

Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet (2007) 2.06

Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med (2005) 2.04

The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med (2005) 1.97

Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis (2009) 1.96

Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol (2008) 1.90

Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet (2011) 1.90

Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc (2010) 1.87

Ten years of bacterial genome sequencing: comparative-genomics-based discoveries. Funct Integr Genomics (2006) 1.86

Update of the Drug Resistance Mutations in HIV-1: 2005. Top HIV Med (2005) 1.83

Estimating HIV Incidence, Time to Diagnosis, and the Undiagnosed HIV Epidemic Using Routine Surveillance Data. Epidemiology (2015) 1.83

Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach. AIDS (2010) 1.82

The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics (2009) 1.80

Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis (2012) 1.76

A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry (2005) 1.74

Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ (2012) 1.71

Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother (2007) 1.70

Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals. J Virol (2009) 1.70

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis (2011) 1.68

Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med (2004) 1.62